Doxercalciferol

CHEMBL1200810 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
412.6 g/mol
LogP
6.3
Phase
4

A synthetic form of vitamin D used to treat secondary hyperparathyroidism in patients with chronic kidney disease. It is activated in the body to help regulate calcium and phosphate levels.

Molekularmasse

412,6000 g/mol

LogP

6,30

TPSA

40,50 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O

InChI

InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1

Molecular Formula

C28H44O2

HBD / HBA

2 / 2

Rotierbare Bindungen

5

Schwere Atome

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A synthetic form of vitamin D used to treat secondary hyperparathyroidism in patients with chronic kidney disease. It is activated in the body to help regulate calcium and phosphate levels.

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Yes, Doxercalciferol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200810. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5281107. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.